Drug Trial Radar · NCT05318573
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
May 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Conditions
- Advanced Urothelial Carcinoma
- Advanced Non Small Cell Lung Cancer
Interventions
PembrolizumabDrug
Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
FF-10832Drug
Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the incidence of Treament Emergent Adverse Events (TEAE)Time frame: 7 years
- Duration of Stable Disease in MonotherapyTime frame: 7 years
- Duration of Stable Disease in Combination TherapyTime frame: 7 years
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Cancer and Blood Speciality Clinic
Long Beach, California
Sharp Memorial Hospital (Oncology Clinical Research)
San Diego, California
Sibley Memorial Hospital
Washington D.C., District of Columbia
University of Kansas Cancer Center - Westwood
Westwood, Kansas
University of Kentucky Medical Center
Lexington, Kentucky
University of Louisville Brown Cancer Center
Louisville, Kentucky
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan
Washington University School of Medicine, Center for Adv Medicine
St Louis, Missouri
Nebraska Cancer Specialists - Legacy
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada - Southern Hills
Las Vegas, Nevada
Atlantic Health System / Morristown Medical Center
Morristown, New Jersey
NYU Langone Health
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
TriHealth Cancer Institute; Good Samaritan Hospital
Cincinnati, Ohio
Providence Cancer Institute Franz Clinic
Portland, Oregon
Hospital of the Univ of Pennsylvania Perlman Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
Sarah Cannon Research Institute
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
University of Wisconsin Clinical Science Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.